Skip to content

IceCure’s ProSense Offered in Arms-On Coaching Course at The American Society of Breast Surgeons Breast Follows Ultrasound Course

  • SOCIETY

Skilled coaching programs are well-timed following IceCure’s FDA submitting for advertising and marketing authorization of ProSense with breakthrough indication

CAESAREA, Israel, Jan 25, 2023 /PRNewswire/ — IceCure Medical Ltd. (Nasdaq: ICCM) (TASE: ICCM) (“IceCure” or the “Firm”), developer of minimally-invasive cryoablation expertise, the ProSense® System that destroys tumors by freezing, right now introduced that on January 13-14, 2023the Firm participated within the American Society of Breast Surgeons (“ASBrS”) Breast Fellows Ultrasound Course in Cincinnati, Ohio. The diagnostic and interventional breast ultrasound course was organized by ASBrS.

The course was moderated by Dr. michael berry and Dr. Richard Effective of the West Most cancers Heart in germantown, Tennessee, each investigators in IceCure’s ICE3 ProSense trial in early-stage, low-risk breast most cancers in sufferers who’re at excessive threat to surgical procedure. Dr. Effective led a session of the course on cryoablation of breast tumors with ProSense and carried out a hands-on workshop and demonstration.

“ProSense was very nicely acquired by course members who received hands-on coaching with our cryoablation system,” said eyal shamir, IceCure’s Chief Govt Officer. “We welcome the ASBrS’s position in addressing the necessity to present extra coaching in ultrasound for breast surgeons, as it’s a key ability needed for performing minimally invasive therapies like cryoablation. Clinician coaching is a crucial element of IceCure’s multifaceted cooperation with the ASBrS with the purpose of advancing the usual of look after breast most cancers.As we stay up for the FDA’s response to our current regulatory submitting for advertising and marketing authorization, conducting consciousness and coaching round cryoablation for breast procedures helps our industrial rollout.”

About IceCure Medical Ltd.

IceCure Medical Ltd. (Nasdaq: ICCM) (TASE: ICCM) develops and markets ProSense®, a sophisticated liquid-nitrogen-based cryoablation remedy for the therapy of tumors (benign and cancerous) by freezing, with the first focus areas being breast, kidney, bone and lung most cancers. Its minimally invasive expertise is a secure and efficient different to hospital surgical tumor elimination that’s simply carried out in a comparatively brief process. The system is marketed and bought worldwide for the indications cleared thus far by the US Meals and Drug Administration (“FDA”) and accepted in Europe with the CE Mark.

Ahead-Trying Statements

This press launch comprises forward-looking statements throughout the which means of the “secure harbor” provisions of the Personal Securities Litigation Reform Act of 1995 and different US federal securities legal guidelines and Israeli securities legal guidelines. Phrases reminiscent of “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and related expressions or variations of such phrases are supposed to determine forward-looking statements. For instance, IceCure is utilizing ahead wanting assertion on this press launch when it discusses: wanting ahead to the FDA’s response to the Firm’s current regulatory submitting for advertising and marketing authorization of ProSense with breakthrough indication; and the advantages of cryoablation as a therapy for breast most cancers. As a result of such statements cope with future occasions and are based mostly on IceCure’s present expectations, they’re topic to numerous dangers and uncertainties and precise outcomes, efficiency or achievements of IceCure might differ materially from these described in or implied by the statements on this press launch. The forward-looking statements contained or implied on this press launch are topic to different dangers and uncertainties, a lot of that are past the management of the Firm, together with these set forth within the Danger Elements part of the Firm’s Annual Report on Type 20-F for the 12 months ended December 31, 2021filed with the Securities and Change Fee (the “SEC”) on April 1, 2022, as amended, which is out there on the SEC’s web site, www.sec.gov. The Firm undertakes no obligation to replace these statements for revisions or adjustments after the date of this launch, besides as required by legislation. References and hyperlinks to web sites have been supplied as a comfort, and the data contained on such web sites shouldn’t be included by reference into this press launch. The Firm shouldn’t be liable for the contents of third-party web sites.

IR Contact:
Ronen Tsimerman
E-mail: [email protected]

SOURCE IceCure Medical Ltd

.

Leave a Reply

Your email address will not be published. Required fields are marked *